Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: HRMY stock price vs RL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RL's multiple
Needs RL P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · RL FY 2026 (ended Mar 28, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
Ralph Lauren Corporation · implied price per share
Bear
$155.32
Base
$182.73
Bull
$210.14
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.58x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
-0.28x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$2.07B
Total debt
Interest-bearing obligations outstanding
$163.66M
$1.64B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
NIKE, Inc.
HRMY vs NKE
V F CORP
HRMY vs VFC
TAPESTRY, INC.
HRMY vs TPR
Capri Holdings Ltd
HRMY vs CPRI
PVH CORP. /DE/
HRMY vs PVH
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY can sustain its superior margins and growth while preserving its clean balance sheet, then the relative-value case supports owning HRMY because it trades at a much lower P/E and EV/EBITDA than RL despite stronger operating metrics.
HRMY trades at a clear valuation discount versus RL across earnings and enterprise-value multiples, even though its operating profile is stronger on several profitability metrics. The current price of $37.26 sits below both RL-implied range and the top end of the historical and DCF ranges, suggesting the market is not pricing in the full relative-value gap.
Supporting Metrics
